AstraZeneca ties up with little Mirati on another PD-L1 combo trial

John Carroll

's big MedImmune subsidiary has a new partner for its closely-watched PD-L1 checkpoint inhibitor durvalumab (MEDI4736). Therapeutics, which is run by some high-profile cancer R&D execs, has struck a deal to pair the therapy with its HDAC inhibitor, mocetinostat, against non-small cell lung cancer.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS